Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis.


Recombinant human alpha-interferon was administered to 15 patients with chronic non-A, non-B hepatitis as a part of a pilot study. Patients received injections of 2 million units per day of interferon three times weekly for 16 wk. The treatment schedule was completed in all but one, whose serum aminotransferase levels were continuously elevated during… (More)


  • Presentations referencing similar topics